Janux Therapeutics (JANX) said late Wednesday it priced a public offering of 5.3 million shares at $63 per share, along with pre-funded warrants for 238,095 shares at $62.999 per warrant.
The offering is expected to raise approximately $350 million in gross proceeds. The underwriters have a 30-day option to purchase up to 833,333 additional shares.
Proceeds from the offering, set to close on Friday, will support the clinical development of the company's product pipeline and general corporate purposes, Janux said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。